Rayno Life Science Biopharmaceutical Portfolio:Cubist(CBST $28.40) Up 12% On Teva Licensing Deal
Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid. Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva...
Rayno Life Science Tools and Dx: Exact Sciences (EXAS) and Qiagen(QGEN)
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent investment conferences. The Company is developing a molecular diagnostic platform for detection of...
Innovation Drives Market Gains in Biopharmaceuticals
This article was published in Genetic Engineering News in the section "Wall Street Biobeat" on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains...
Decent Follow Through From Yesterday’s Biotech Rally
Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday's M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF's-IBB FBT XBI- also gained about 0.5%.Amgen(AMGN) was...
Caution on Optimer (OPTR) Down 3% in Strong Biotech Market-update April 1 OPTR up 11%
Optimer soars 11% to $13.13 on presentation of Shea Data and preliminary FDA review: Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients - Yahoo! Finance Optimer Rises After FDA Staff Says...